FDA's Oncologic Drugs Advisory Committee
On Jan. 31 will discuss Burroughs Wellcome's Alkeran (melphalan) injection (NDA 20-207) for hyperthermic-isolated limb perfusion as an adjunct to surgery for locally-advanced malignant melanoma of the extremities and for palliative treatment of multiple melanoma. The committee will also review U.S. Bioscience's Ethyol (amifostine) injection (NDA 20-221) as a protective agent against toxicities from intensive regimens of platinum and alkylating agent chemotherapy. The meeting will start at 8 a.m. in Conference Rooms D & E at FDA's Parklawn Building. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth